Managing peripheral edema in patients with arterial hypertension

American Journal of Therapeutics

Volumn 16, Issue 6, 2009, Pages 543-553

  Epstein, Benjamin J ^a,b   Roberts, Mary Ellen ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b East Coast Institute for Research   (United States)

^c Clinical and Invasive Cardiology PA   (United States)

Author keywords

Antihypertensives; Combination therapy; Edema; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMLODIPINE BESYLATE; BENAZEPRIL; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CORTICOSTEROID; DIAZOXIDE; DIHYDROPYRIDINE; ESTROGEN; GUANETHIDINE; HORMONE DERIVATIVE; HYDRALAZINE; METHYLDOPA; MINOXIDIL; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLALKYLAMINE; PHENYLBUTAZONE; PIOGLITAZONE; PROGESTERONE; RESERPINE; ROSIGLITAZONE; STEROID; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; TROGLITAZONE; UNINDEXED DRUG;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG MEGADOSE; HUMAN; HYPERTENSION; LEG EDEMA; LIFESTYLE MODIFICATION; MONOTHERAPY; MOTIVATION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; EDEMA; HUMANS; HYPERTENSION;

EID: 74549200870     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181afbf9f     Document Type: Review

References (50)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-146.
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
4. Mancia G, de Backer G, Dominiczak A, et al. 2007 ESHESC Guidelines for the management of arterial hypertension. Blood Press. 2007; 16:135-232.
5. Pre-Diabetes ACoETFo. American College of Endocrinology Consensus Statement on the Diagnosis and Management of Pre-diabetes in the Continuum of Hyperglycemia: When Do the Risks of Diabetes Begin? Jacksonville, FL: American College of Endocrinology; 2008.
6. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115: 2761-2788.
7. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-2051.
8. Staessen JA, Thijisq L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22:847-857.
9. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
11. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
12. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
13. Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens. 2005;19:491-496.
14. Brachmann J, Ansari A, Mahla G, et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther. 2008;25:399-411.
15. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587-604.
16. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580.
17. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007;9:355-364.
18. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326: 1427-1434.
19. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a doubleblind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61-73.
20. Weir MR: Risk-based classification of hypertension and the role of combination therapy. J Clin Hypertens (Greenwich). 2008;10:4-12.
21. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155-2163.
22. Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens. 2008;21:1076-1085.
23. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345:861-869. (Pubitemid 34940825)
24. Egido J, Ruiz-Ortega M. Anti-inflammatory actions of quinapril. Cardiovasc Drugs Ther. 2007;21:211-220.
25. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153. (Pubitemid 30051645)
26. Jamerson KA, on behalf of the ACCOMPLISH investigators. Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension. Presented at the American College of Cardiology Scientific Sessions, March 31, 2008, Chicago, IL.
27. Cho S, Atwood JE. Peripheral edema. Am J Med. 2002;113: 580-586.
28. Schroth BE. Evaluation and management of peripheral edema. JAAPA. 2005;18:29-34.
29. Braunwald E, Loscalzo J. Edema. In: Fauci AS, Braunwald E, Kasper DL, et al (eds). Harrison's Principles of Internal Medicine. 17th ed. New York, NY: The McGraw-Hill Companies, Inc.; 2008.
30. Messerli FH. Evolution of calcium antagonists: past, present, and future. Clin Cardiol. 2003;26:II12-II16.
31. Ereso AQ, Ramirez RM, Sadjadi J, et al. Angiotensin II type 2 receptor provides an endogenous brake during inflammation-induced microvascular fluid leak. J Am Coll Surg. 2007;205:527-533.
32. Kaya M, Kalayci R, Kucuk M, et al. Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats. Life Sci. 2003;73:3235-3244.
33. Newton CR, Curran B, Victorino GP. Angiotensin II type 2 receptor effect on microvascular hydraulic permeability. J Surg Res. 2004;120:83-88. (Pubitemid 38686533)
34. Chrysant SG: Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/ olmesartan combination. Drugs Today (Barc). 2008;44:443-453.
35. Chrysant SG, Sugimoto DH, Lefkowitz M, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press. 2007;16:10-17.
36. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens. 2008;2:294-302.
37. Flack J, Calhoun D, Satlin L, et al. Efficacy and safety of amlodipine/valsartan combination therapy compared with amlodipine monotherapy in black patients with stage 2 hypertension. Presented at the American Society of Hypertension Annual Scientific Meeting and Exposition, May 14-17, 2008, New Orleans, LA.
38. Fogari R, Malamani G, Zoppi A, et al. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. Clin Ther. 2007;29:413-418.
39. Fogari R, Malamani GD, Zoppi A, et al. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2003;17:207-212.
40. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220-224.
41. Mohler ER III, Herrington D, Ouyang P, et al. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. J Clin Hypertens (Greenwich). 2006;8:692-698.
42. Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension. Am J Geriatr Cardiol. 2006;15: 142-150.
43. Schrader J, Weisskopf M, Keeling L, et al. The combination of amlodipine/valsartan (5/160 mg) significantly reduces the incidence of peripheral edema versus amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. J Hypertens. 2008;26(Suppl 1):S478.
44. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure After Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008;10: 185-194.
45. Fogari R, Derosa G, Zoppi A, et al. Effects of manidipine/ delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens Res. 2008;31: 43-50.
46. Kereiakes DJ, Neutel JM, Punzi HA, et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs. 2007;7:361-372.
47. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002;15: 550-556.
48. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279-289.
49. Sica DA: Calcium channel blocker-related peripheral edema: can it be resolved? J Clin Hypertens (Greenwich). 2003;5:291-297.
50. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixeddose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-719.